Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of JTE-061 Cream in Pediatric Atopic Dermatitis
jRCT2031210257Phase 2Completed
- Sponsor
- Japan Tobacco
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tapinarof in atopic dermatitis (AD) (3 arms), sponsored by Japan Tobacco. Primary endpoint: Mean percent change in EASI score from baseline at Week 8. Started Sep 2021; status: completed.
02
Drugs
tapinarof
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031210257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210257.